Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XVTBW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TAK-ATACs
|
|||||
| Synonyms |
TAK ATACs; TAKATACs
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma AG; Takeda Pharmaceutical Co., Ltd.; Heidelberg Pharma Research GmbH; Heidelberg Pharma AG
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.